Exact Mass: 809.3312132000001

Exact Mass Matches: 809.3312132000001

Found 21 metabolites which its exact mass value is equals to given mass value 809.3312132000001, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

MA 144 Y

methyl (1R,2R,4S)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-4-O-{2,6-dideoxy-4-O-[(2R,6S)-6-methyl-5-oxo-5,6-dihydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl}-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate

C42H51NO15 (809.3258536)

D000970 - Antineoplastic Agents D007155 - Immunologic Factors

Aclacinomycin B

methyl 4-{[5-({5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0^{3,8}]tetradecan-12-yl}oxy)-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate

C42H51NO15 (809.3258536)

D000970 - Antineoplastic Agents D007155 - Immunologic Factors

Aclacinomycin Y

methyl 4-{[4-(dimethylamino)-5-({4-hydroxy-6-methyl-5-[(6-methyl-5-oxo-5,6-dihydro-2H-pyran-2-yl)oxy]oxan-2-yl}oxy)-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate

C42H51NO15 (809.3258536)

D000970 - Antineoplastic Agents D007155 - Immunologic Factors

FCE 24366

C40H47N3O15 (809.3007032)

Aclacinomycin B

C42H51NO15 (809.3258536)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D000970 - Antineoplastic Agents D007155 - Immunologic Factors

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D012294 - Rifamycins C254 - Anti-Infective Agent > C258 - Antibiotic

(1R,2R,4S)-2-ethyl-2,7-dihydroxy-1-(methoxycarbonyl)-6,11-dioxo-4-{[2,3,6-trideoxy-4-O-{2,6-dideoxy-4-O-[(2R,6S)-6-methyl-5-oxo-5,6-dihydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl}-3-(dimethylazaniumyl)-alpha-L-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracen-5-olate

(1R,2R,4S)-2-ethyl-2,7-dihydroxy-1-(methoxycarbonyl)-6,11-dioxo-4-{[2,3,6-trideoxy-4-O-{2,6-dideoxy-4-O-[(2R,6S)-6-methyl-5-oxo-5,6-dihydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl}-3-(dimethylazaniumyl)-alpha-L-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracen-5-olate

C42H51NO15 (809.3258536)

2-[3-[(3S,3S,4R,6S,8R,8aR)-8-[1-azocanyl(oxo)methyl]-6-(4-hydroxyphenyl)-1,2-dioxo-3,4-diphenyl-5-spiro[1H-indole-3,7-4,6,8,8a-tetrahydro-3H-pyrrolo[2,1-c][1,4]oxazine]yl]prop-2-ynyl]propanedioic acid dimethyl ester

2-[3-[(3S,3S,4R,6S,8R,8aR)-8-[1-azocanyl(oxo)methyl]-6-(4-hydroxyphenyl)-1,2-dioxo-3,4-diphenyl-5-spiro[1H-indole-3,7-4,6,8,8a-tetrahydro-3H-pyrrolo[2,1-c][1,4]oxazine]yl]prop-2-ynyl]propanedioic acid dimethyl ester

C48H47N3O9 (809.3312132000001)

methyl (1R,2R,4S)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-4-O-{2,6-dideoxy-4-O-[(2R,6S)-6-methyl-5-oxo-5,6-dihydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl}-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate

C42H51NO15 (809.3258536)

D000970 - Antineoplastic Agents D007155 - Immunologic Factors

aclacinomycin Y zwitterion

C42H51NO15 (809.3258536)

A zwitterion obtained by transfer of a proton from the 5-hydroxy to the tertiary amino group of aclacinomycin Y. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).

Aclacinomycin y

C42H51NO15 (809.3258536)

An anthracycline antibiotic that is aclacinomycin A in which the ketone function on the trisaccharide fragment has undergone 2,3-dehydrogenation to afford the corresponding enone.

5-[(2r,4r,5s,6as,8s,10r,10as)-8-{[(1r,3s)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-2,4-dihydro-1h-tetracen-1-yl]oxy}-2-[(2s)-2-hydroxypropyl]-4,10-dimethyl-octahydro-2h-pyrano[3,4-d][1,3,6]dioxazocin-5-yl]-1,3-dimethyl-1,3-diazinane-2,4,6-trione

5-[(2r,4r,5s,6as,8s,10r,10as)-8-{[(1r,3s)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-2,4-dihydro-1h-tetracen-1-yl]oxy}-2-[(2s)-2-hydroxypropyl]-4,10-dimethyl-octahydro-2h-pyrano[3,4-d][1,3,6]dioxazocin-5-yl]-1,3-dimethyl-1,3-diazinane-2,4,6-trione

C40H47N3O15 (809.3007032)

methyl (1r,2r,4s)-4-{[(2r,4s,5s,6s)-5-{[(1r,3r,5s,8r,10s,12r,14s)-5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl]oxy}-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate

methyl (1r,2r,4s)-4-{[(2r,4s,5s,6s)-5-{[(1r,3r,5s,8r,10s,12r,14s)-5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl]oxy}-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate

C42H51NO15 (809.3258536)

2-[17-(3-aminopropyl)-11-benzyl-5-[(5-chloro-1h-indol-3-yl)methyl]-3,6,9,12,15,18-hexahydroxy-8,14-diisopropyl-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]-2-hydroxyethanimidic acid

2-[17-(3-aminopropyl)-11-benzyl-5-[(5-chloro-1h-indol-3-yl)methyl]-3,6,9,12,15,18-hexahydroxy-8,14-diisopropyl-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]-2-hydroxyethanimidic acid

C39H52ClN9O8 (809.3627182)

methyl 4-{[4-(dimethylamino)-6-methyl-5-({6-methyl-5-[(6-methyl-5-oxo-2,6-dihydropyran-2-yl)oxy]oxan-2-yl}oxy)oxan-2-yl]oxy}-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate

methyl 4-{[4-(dimethylamino)-6-methyl-5-({6-methyl-5-[(6-methyl-5-oxo-2,6-dihydropyran-2-yl)oxy]oxan-2-yl}oxy)oxan-2-yl]oxy}-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate

C42H51NO15 (809.3258536)